TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2366602

Group type: EXPERIMENTAL
Intervention: Arthritis Impact Measurement Scales (AIMS)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Functional Status Index (FSI)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire (HAQ)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Index of Well Being (IWB)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sickness Impact Profile (SIP)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: All instruments
Number of subjects: 38
Study: 518245

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term interpersonal psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of amitriptyline and psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonscheduled treatment control group
Number of subjects: 0
Study: 31161592

Group type: EXPERIMENTAL
Intervention: Intervention app (n=25)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control app (n=20)
Number of subjects: 45
Study: 28732834

Group type: EXPERIMENTAL
Intervention: Inhaler reminders via SmartTrack adherence monitors (Adherium Ltd)
Number of subjects: 18
Study: 26040221

Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Ranibizumab + laser
Number of subjects: 220

Group type: COMPARATOR
Intervention: Laser monotherapy
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy and ranibizumab + laser
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Safety profile
Number of subjects: 220
Study: 24066704

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 4 months, delivered in 20 individual outpatient sessions.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting-list control condition (C).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT).
Number of subjects: 60
Study: 21895039

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (oral, direct Factor Xa inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg once daily) in patients with AF with creatinine clearance of 30-49 mL/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prothrombin time
Number of subjects: 0
Study: 19304928

Group type: EXPERIMENTAL
Intervention: DOiT intervention
Number of subjects: 0
Study: 18214218

Group type: EXPERIMENTAL
Intervention: Various interventions to enhance adherence to ART, specific interventions not detailed in the abstract.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized short-term interventions tested by randomized controlled trials.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term programs tailored to the patient's needs.
Number of subjects: 0
Study: 15106686

Group type: EXPERIMENTAL
Intervention: Inferior alveolar block/long buccal infiltration anesthesia
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Infiltration/intrapapillary injection
Number of subjects: 101
Study: 11758006

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sitting with CPAP of 8 cm H2O
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 10
Study: 9750937

Group type: EXPERIMENTAL
Intervention: A-308 genotype (T2)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: A-308 transition genotype
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: A-238 transition genotype
Number of subjects: 78
Study: 8525757

Group type: EXPERIMENTAL
Intervention: Behavioral Treatment Program (BHG) including deep muscle relaxation, peripheral temperature Biofeedback, and anxiety management training
Number of subjects: 21
Study: 3396576

Group type: EXPERIMENTAL
Intervention: HFHP diet (low CHO, high fat, high protein)
Number of subjects: 6

Group type: COMPARATOR
Intervention: N diet (normal diet)
Number of subjects: 6

Group type: COMPARATOR
Intervention: HCLF diet (high CHO, low fat, normal protein)
Number of subjects: 6
Study: 31445509

Group type: EXPERIMENTAL
Intervention: Preformed pediatric zirconia crowns (EZCrowns, Sprig Oral Health Technologies)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Preformed pediatric stainless steel crowns (ESPE, 3M)
Number of subjects: 101
Study: 28841916

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (four cycles FOLFIRINOX) followed by resection
Number of subjects: 90

Group type: COMPARATOR
Intervention: Surgery first (control group) followed by adjuvant chemotherapy (six cycles gemcitabine and capecitabine)
Number of subjects: 90
Study: 25662348

Group type: EXPERIMENTAL
Intervention: modified Story Memory Technique (mSMT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 23726291

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800mg once daily for 14 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Simvastatin (SMV) 80mg administered alone
Number of subjects: 24
Study: 21212398

Group type: EXPERIMENTAL
Intervention: Door-to-door stroke case ascertainment
Number of subjects: 2437

Group type: COMPARATOR
Intervention: Hospital surveillance
Number of subjects: 2437
Study: 18712963

Group type: EXPERIMENTAL
Intervention: Breast Self-Examination (BSE)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Clinical Breast Examination (CBE)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Breast cancer knowledge
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Awareness of breast cancer screening (BCS)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Regular visit with a physician
Number of subjects: 425

Group type: COMPARATOR
Intervention: Age, family history of breast cancer, marital status, health insurance
Number of subjects: 425
Study: 16098942

Group type: EXPERIMENTAL
Intervention: Sinusoidal oscillations at 3 Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole image motion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eye movements during image motion
Number of subjects: 0
Study: 12554315

Group type: EXPERIMENTAL
Intervention: Educational intervention targeted at both patient and spouse
Number of subjects: 24

Group type: COMPARATOR
Intervention: Patient education intervention targeted at only the patient
Number of subjects: 24
Study: 11129675

Group type: EXPERIMENTAL
Intervention: Elevated Lp(a) levels
Number of subjects: 202
Study: 9396639

Group type: EXPERIMENTAL
Intervention: Enoxaparin-ticlopidine-aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (ticlopidine, aspirin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenocoumaron and aspirin
Number of subjects: 0
Study: 8450381

Group type: EXPERIMENTAL
Intervention: Iron-fortified formula (3 mg/L)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Iron-fortified formula (6 mg/L)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 3
Study: 3312212

Group type: EXPERIMENTAL
Intervention: Topical steroid (Aristocort A)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Topical vitamin E
Number of subjects: 159

Group type: COMPARATOR
Intervention: Base cream carrier
Number of subjects: 159
Study: 30466845

Group type: EXPERIMENTAL
Intervention: CRT-D with posterior/lateral LV lead location
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: CRT-D with anterior LV lead location
Number of subjects: 797

Group type: COMPARATOR
Intervention: CRT-D (any lead location)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: CRT-D with apical LV lead location
Number of subjects: 797

Group type: COMPARATOR
Intervention: ICD only
Number of subjects: 797
Study: 27007650

Group type: EXPERIMENTAL
Intervention: Totally tubeless percutaneous nephrolithotomy (PCNL)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard percutaneous nephrolithotomy (PCNL)
Number of subjects: 84
Study: 25608093

Group type: EXPERIMENTAL
Intervention: Computer-based learning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional classroom learning
Number of subjects: 0
Study: 23857197

Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg intravenous midazolam (high dose)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.035 mg/kg intravenous midazolam (low dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Midazolam (both doses)
Number of subjects: 100
Study: 19961264

Group type: EXPERIMENTAL
Intervention: Talampanel 50 mg p.o. t.i.d
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 18086066

Group type: EXPERIMENTAL
Intervention: Bupivacaine (1 mg x kg(‐1)) and pethidine (1 mg x kg(‐1)) in adrenaline 1:200,000
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (placebo group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bupivacaine and pethidine
Number of subjects: 80
Study: 16896953

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pergolide (0.1 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14633807

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 522

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 522
Study: 10928235

Group type: EXPERIMENTAL
Intervention: IAsp (0.15 IU/kg body weight) immediately before the meal
Number of subjects: 25

Group type: COMPARATOR
Intervention: Actrapid (0.15 IU/kg) immediately before the meal (Act0)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Actrapid (0.15 IU/kg) 30 minutes before the meal (Act-30)
Number of subjects: 25
Study: 8616414

Group type: EXPERIMENTAL
Intervention: n of 1 trials (theophylline)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard practice (theophylline stopped and resumed based on dyspnoea)
Number of subjects: 31
Study: 1451921

Group type: EXPERIMENTAL
Intervention: Vivida cream applied twice daily for 120 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 30
Study: 6087475

Group type: EXPERIMENTAL
Intervention: Tendamistate (100 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Guar (5 g)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29995679

Group type: EXPERIMENTAL
Intervention: High-volume hospitals (≥21 surgeries/year)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Low-volume hospitals (1-20 surgeries/year)
Number of subjects: 494
Study: 28930060

Group type: EXPERIMENTAL
Intervention: Computer BI
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Therapist BI
Number of subjects: 555
Study: 25733640

Group type: EXPERIMENTAL
Intervention: Enteral protein feeding (hypocaloric-hyponitrogenous)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Stable parenteral amino acid supply (n = 7)
Number of subjects: 10
Study: 24570635

Group type: EXPERIMENTAL
Intervention: Single-incision CTR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-incision CTR
Number of subjects: 0
Study: 21971483

Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism
Number of subjects: 1999

Group type: EXPERIMENTAL
Intervention: Clinical hypothyroidism
Number of subjects: 1999

Group type: EXPERIMENTAL
Intervention: Subclinical hyperthyroidism
Number of subjects: 1999

Group type: EXPERIMENTAL
Intervention: Clinical hyperthyroidism
Number of subjects: 1999

Group type: EXPERIMENTAL
Intervention: Positive TPOAb
Number of subjects: 1999
Study: 19609054

Group type: EXPERIMENTAL
Intervention: Telmisartan (20-80 mg/d)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Perindopril (2-8 mg/d)
Number of subjects: 51
Study: 17465659

Group type: EXPERIMENTAL
Intervention: UDMA adhesive with 30 vol% filler
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: UDMA adhesive with 50 vol% filler
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: UDMA adhesive with 70 vol% filler
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Unfilled UDMA adhesive
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study: 15672598

Group type: EXPERIMENTAL
Intervention: PsychoedPlusMed (psychoeducational intervention combined with sildenafil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sildenafil only (control group)
Number of subjects: 0
Study: 16003539

Group type: EXPERIMENTAL
Intervention: Single-set group (SSG)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Multiple-set group (MSG)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: ACE II genotype in MST group
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: ACE DD genotype in SSG and MSG
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: ACE ID genotype in SSG
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: ACE DD genotype in both training groups
Number of subjects: 99
Study: 10690150

Group type: COMPARATOR
Intervention: saline i.v. (group I, n = 62)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: droperidol 2.5 mg i.v. (group 2, n = 60)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg i.v. (group 3, n = 57)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: droperidol 2.5 mg with ondansetron 4 mg i.v. (group 4, n = 63)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: droperidol and ondansetron combination
Number of subjects: 242
Study: 8920850

Group type: EXPERIMENTAL
Intervention: Reconstituted high-density lipoprotein (rHDL) infusion at 40 mg/kg for 4 hours before endotoxin challenge (4 ng/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reconstituted high-density lipoprotein (rHDL) infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monocytes isolated from rHDL-treated whole blood
Number of subjects: 0
Study: 1864205

Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg/day
Number of subjects: 4524

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 4524
Study: 6356758

Group type: EXPERIMENTAL
Intervention: THIP (4, 5, 6, 7‐tetrahydroisoxazolo (5,4‐) pyridin‐3‐ol)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6
Study: 30009423

Group type: EXPERIMENTAL
Intervention: Self-distancing (third-person perspective)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Self-distancing (competent media character perspective)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Self-immersed perspective
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (no self-distancing)
Number of subjects: 139
Study: 29022411

Group type: EXPERIMENTAL
Intervention: Notched noise (1000‐12,000Hz notched within a 1‐octave range centred around the tinnitus pitch match frequency)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Matched noise (1‐octave wide band of noise centred around the PM frequency)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (low frequency noise 250‐700Hz)
Number of subjects: 30
Study: 26794605

Group type: EXPERIMENTAL
Intervention: MTX plus hydroxychloroquine plus sulphasalazine plus low dose prednisone (arm 1)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: MTX plus adalimumab (arm 2)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Early remission group (patients who achieved early DAS-remission after 4 months)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: RA patients
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: UA patients
Number of subjects: 610
Study: 24459683

Group type: EXPERIMENTAL
Intervention: PVP-iodine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 12
Study: 22699168

Group type: EXPERIMENTAL
Intervention: Smoking cessation education
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 20236548

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated split virion influenza vaccine (TIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17394970

Group type: EXPERIMENTAL
Intervention: Heparin (unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibition (GPI)
Number of subjects: 13819

Group type: EXPERIMENTAL
Intervention: Bivalirudin plus GPI
Number of subjects: 13819

Group type: COMPARATOR
Intervention: Bivalirudin monotherapy (plus provisional GPI)
Number of subjects: 13819

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 13819
Study: 15760638

Group type: EXPERIMENTAL
Intervention: MELAS patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 11849382

Group type: EXPERIMENTAL
Intervention: High sodium diet (250 mmol/day) during the luteal phase
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low sodium diet (40 mmol/day) during the follicular phase
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High sodium diet (250 mmol/day) during the follicular phase
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low sodium diet (40 mmol/day) during the luteal phase
Number of subjects: 35
Study: 10188715

Group type: EXPERIMENTAL
Intervention: Fiber intake
Number of subjects: 12763

Group type: EXPERIMENTAL
Intervention: Vitamin B6 intake
Number of subjects: 12763

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol intake
Number of subjects: 12763

Group type: COMPARATOR
Intervention: Plant foods and related sub-groups
Number of subjects: 12763
Study: 7818125

Group type: EXPERIMENTAL
Intervention: Atracurium 450 micrograms/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vecuronium 80 micrograms/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mivacurium 160 micrograms/kg
Number of subjects: 10
Study: 30379683

Group type: EXPERIMENTAL
Intervention: Premium DM/NR features
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Premium HAs
Number of subjects: 54

Group type: COMPARATOR
Intervention: DM/NR features
Number of subjects: 54

Group type: COMPARATOR
Intervention: Basic DM/NR features
Number of subjects: 54
Study: 28923039

Group type: EXPERIMENTAL
Intervention: Calmagen® cream or lotion
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (inert topical preparation)
Number of subjects: 28
Study: 25809680

Group type: EXPERIMENTAL
Intervention: 400-kcal macronutrient and fiber-matched (MF) beef protein (24-g)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 400-kcal serving size-matched (SS) beef protein (24-g)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 400-kcal macronutrient and fiber-matched (MF) soy protein (24-g)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 400-kcal serving size-matched (SS) soy protein (14-g)
Number of subjects: 21
Study: 23716559

Group type: EXPERIMENTAL
Intervention: Bortezomib-dexamethasone
Number of subjects: 163
Study: 21316088

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17653957

Group type: EXPERIMENTAL
Intervention: 0.625/2.5 mg CE/MPA for 6 months
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: 0.45/1.5 mg CE/MPA for 6 months
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: 0.3/1.5 mg CE/MPA for 6 months
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: 0.625/2.5 mg CE/MPA
Number of subjects: 1028
Study: 16403987

Group type: EXPERIMENTAL
Intervention: Vitamin C (200 mg/day) plus Aspirin (300 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (300 mg/day)
Number of subjects: 0
Study: 11812877

Group type: COMPARATOR
Intervention: Calcium carbonate (3 g/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ferric citrate (3 g/day)
Number of subjects: 45
Study: 10609622

Group type: EXPERIMENTAL
Intervention: HFA albuterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CFC albuterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8953501

Group type: EXPERIMENTAL
Intervention: 10 mM phosphate, pH 7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mM phosphate, pH 6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mM phosphate, pH 6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hIGF‐I
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 0
Study: 1844327

Group type: EXPERIMENTAL
Intervention: Multiload IUD
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Gravigard IUD
Number of subjects: 236

Group type: COMPARATOR
Intervention: Short IUD-types
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Longer IUDs
Number of subjects: 236

Group type: COMPARATOR
Intervention: Total uterine cavity length < 7 cm
Number of subjects: 236

Group type: COMPARATOR
Intervention: IUD insertion in nulligravidae
Number of subjects: 236

Group type: COMPARATOR
Intervention: Length of uterine cavity vs length of IUD
Number of subjects: 236
Study: 7104637

Group type: EXPERIMENTAL
Intervention: Antibiotic group
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Exploration of the common bile duct
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Cholecystectomy alone
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Microscopy of bile
Number of subjects: 111
Study: 31030005

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 56
Study: 29544501

Group type: COMPARATOR
Intervention: Direct Control (DC)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: EMG Pattern Recognition (PR)
Number of subjects: 2
Study: 27776494

Group type: EXPERIMENTAL
Intervention: Mild-warm moxibustion group (moxa stick 3-5 cm away from acupuncture points, skin temperature 43±1 °C)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo moxibustion group (moxa stick 8-10 cm away from acupuncture points, skin temperature 37±1 °C)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Mild-warm moxibustion group
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo moxibustion group
Number of subjects: 104
Study: 24789677

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham direct current stimulation
Number of subjects: 10
Study: 22015462

Group type: EXPERIMENTAL
Intervention: Optibond FL
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: G Bond
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Other adhesive systems (etch and rinse and self-etch)
Number of subjects: 12